Monitor the tender offer statement expected to be filed June 3, 2026 for detailed terms of the option exchange. The rejection of executive option exchange suggests potential retention risk for senior management, but no immediate trading catalyst.
Price Chart
Executive Summary
REGENXBIO reported results of its 2026 Annual Meeting held May 29, 2026, where shareholders elected three Class II directors, ratified PwC as auditor, approved non-executive stock option exchange program, and did NOT approve a similar program for executives. The company commenced the non-executive option exchange program on June 3, 2026, with an offer period running through July 1, 2026. This is a routine governance and compensation event with no material financial impact disclosed.
Key Facts
- Annual Meeting held May 29, 2026 with 42,818,883 shares represented (~82.95% of eligible shares)
- Shareholders elected Jean Bennett, A.N. Jerry Karabelas, and Daniel Tass as Class II directors
- Ratified PricewaterhouseCoopers LLP as independent auditor for FY2026
- Approved non-executive employee stock option exchange program (26.4M for, 8.9M against)
- Did NOT approve executive stock option exchange program (14.1M for, 21.0M against)
- Non-executive option exchange program commenced June 3, 2026; offer period ends July 1, 2026
- Exchange program applies to options with exercise price ≥ $18.00; new options priced at fair market value on grant date
- Company states exchange program not expected to result in significant change to stock compensation expense
Financial Impact
No material financial impact disclosed; company states stock compensation expense not expected to change significantly
Risk Factors
- Executive option exchange rejection may signal dissatisfaction with pay structure or governance
- Option exchange could modestly reduce dilution if underwater options are surrendered
- No financial guidance or operational update provided in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-254590 |
| Document: 0001193125-26-254590-index.html | 0001193125-26-254590 |
| Document: 0001193125-26-254590.txt | 0001193125-26-254590 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | Insider Buy | $9.66 $7.47 | ▼ −22.67% | ▼ −22.93% | $7.43 (−23.08%) |
Aug 25, 2026 5w ago | 8-K | $9.38 $7.24 | ▼ −22.81% | ▼ −23.04% | $7.43 (−20.79%) |
Aug 6, 2026 8w ago | 8-K | $11.28 $9.20 | ▼ −18.44% | ▼ −19.04% | $7.43 (−34.13%) |
Aug 3, 2026 8w ago | Press Release | $9.96 $9.50 | ▼ −4.62% | ▼ −5.86% | $7.43 (−25.40%) |
Jul 20, 2026 10w ago | 8-K | $10.32 $11.33 | ▼ −9.79% | ▼ −5.67% | $7.43 (+28.00%) |
Jul 17, 2026 11w ago | Press Release | $9.89 $10.77 | ▼ −8.85% | ▼ −4.40% | $7.43 (+24.87%) |
Jun 29, 2026 13w ago | 8-K | $11.83 $9.73 | ▼ −17.75% | ▼ −17.47% | $7.43 (−37.19%) |
Jun 3, 2026 17w ago | 8-K | $6.69 $13.28 | ▲ +98.51% | ▲ +99.51% | $7.43 (+11.06%) |
May 14, 2026 20w ago | 8-K | $6.25 $6.66 | ▲ +6.65% | ▲ +7.50% | $7.43 (+18.98%) |
Mar 5, 2026 30w ago | 8-K | $8.72 $8.53 | ▼ −2.18% | ▲ +1.61% | $7.43 (−14.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access